210 related articles for article (PubMed ID: 38746071)
1. Benefits of intravenous iron supplementation in heart failure.
Kotit S
Glob Cardiol Sci Pract; 2024 Mar; 2024(2):e202410. PubMed ID: 38746071
[No Abstract] [Full Text] [Related]
2. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Rosano G; Ponikowski P; Vitale C; Anker SD; Butler J; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Metra M; Ruschitzka F; Kumpeson V; Goehring UM; van der Meer P; Jankowska EA;
Cardiovasc Diabetol; 2023 Aug; 22(1):215. PubMed ID: 37592272
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis.
Khan MS; Usman MS; von Haehling S; Doehner W; Stewart Coats AJ
ESC Heart Fail; 2020 Dec; 7(6):3392-3400. PubMed ID: 33586856
[TBL] [Abstract][Full Text] [Related]
9. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Metra M; Jankowska EA; Pagnesi M; Anker SD; Butler J; Dorigotti F; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Rosano G; Ruschitzka F; Tomasoni D; van der Meer P; Ponikowski P;
Eur J Heart Fail; 2022 Oct; 24(10):1928-1939. PubMed ID: 35869741
[TBL] [Abstract][Full Text] [Related]
10. Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Macdougall IC; Ponikowski P; Stack AG; Wheeler DC; Anker SD; Butler J; Filippatos G; Göhring UM; Kirwan BA; Kumpeson V; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1124-1134. PubMed ID: 37382961
[TBL] [Abstract][Full Text] [Related]
11. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.
Vukadinović D; Abdin A; Emrich I; Schulze PC; von Haehling S; Böhm M
Clin Res Cardiol; 2023 Jul; 112(7):954-966. PubMed ID: 37074386
[TBL] [Abstract][Full Text] [Related]
13. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
15. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
[TBL] [Abstract][Full Text] [Related]
16. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA
Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652
[TBL] [Abstract][Full Text] [Related]
17. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
[TBL] [Abstract][Full Text] [Related]
18. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis.
Dalal J; Katekhaye V; Jain R
Indian Heart J; 2017; 69(6):736-741. PubMed ID: 29174251
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
[TBL] [Abstract][Full Text] [Related]
20. Iron Deficiency: A New Target for Patients With Heart Failure.
Rizzo C; Carbonara R; Ruggieri R; Passantino A; Scrutinio D
Front Cardiovasc Med; 2021; 8():709872. PubMed ID: 34447793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
